CN114224875A - 醇类化合物的新用途及抗肿瘤药物 - Google Patents
醇类化合物的新用途及抗肿瘤药物 Download PDFInfo
- Publication number
- CN114224875A CN114224875A CN202111299645.6A CN202111299645A CN114224875A CN 114224875 A CN114224875 A CN 114224875A CN 202111299645 A CN202111299645 A CN 202111299645A CN 114224875 A CN114224875 A CN 114224875A
- Authority
- CN
- China
- Prior art keywords
- propranolol
- cells
- hydroxy
- tumor
- isopropylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
试剂名称 | 用量(mL) |
双蒸水 | 4.0 |
30%甲叉双丙烯酰胺 | 3.3 |
1.5M Tris-HCl(pH 8.8) | 2.5 |
10%十二烷基磺酸钠 | 0.1 |
10%过硫酸铵 | 0.1 |
四甲基乙二胺 | 0.004 |
总体积 | 10 |
试剂名称 | 用量(mL) |
双蒸水 | 2.7 |
30%甲叉双丙烯酰胺 | 0.67 |
1M Tris-HCl(pH 6.8) | 0.5 |
10%十二烷基磺酸钠 | 0.04 |
10%过硫酸铵 | 0.04 |
四甲基乙二胺 | 0.004 |
总体积 | 8.4 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111299645.6A CN114224875B (zh) | 2021-11-04 | 2021-11-04 | 醇类化合物的新用途及抗肿瘤药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111299645.6A CN114224875B (zh) | 2021-11-04 | 2021-11-04 | 醇类化合物的新用途及抗肿瘤药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114224875A true CN114224875A (zh) | 2022-03-25 |
CN114224875B CN114224875B (zh) | 2023-08-11 |
Family
ID=80743761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111299645.6A Active CN114224875B (zh) | 2021-11-04 | 2021-11-04 | 醇类化合物的新用途及抗肿瘤药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114224875B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1066613A (en) * | 1965-03-03 | 1967-04-26 | Ici Ltd | Naphthalene derivatives |
AU2002328953A1 (en) * | 2001-07-23 | 2003-02-24 | Epidauros Biotechnologie Ag | Use of irinotecan for improved treatment of cancer based on mdr1 |
WO2009070609A2 (en) * | 2007-11-27 | 2009-06-04 | The Board Of Regents Of The University Of Texas System | Therapeutic targeting of il-6 using sirna in neutral liposomes |
CN102871956A (zh) * | 2012-10-29 | 2013-01-16 | 中南大学湘雅医院 | 一种治疗婴幼儿浅表血管瘤的盐酸普萘洛尔凝胶 |
CN107569485A (zh) * | 2017-07-24 | 2018-01-12 | 中南大学湘雅医院 | 一种治疗braf抑制剂耐药型黑色素瘤的复方制剂 |
CN110314154A (zh) * | 2018-03-28 | 2019-10-11 | 武汉恒信源药业有限公司 | 左旋普萘洛尔在制备治疗血管病变药物中的应用 |
-
2021
- 2021-11-04 CN CN202111299645.6A patent/CN114224875B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1066613A (en) * | 1965-03-03 | 1967-04-26 | Ici Ltd | Naphthalene derivatives |
AU2002328953A1 (en) * | 2001-07-23 | 2003-02-24 | Epidauros Biotechnologie Ag | Use of irinotecan for improved treatment of cancer based on mdr1 |
WO2009070609A2 (en) * | 2007-11-27 | 2009-06-04 | The Board Of Regents Of The University Of Texas System | Therapeutic targeting of il-6 using sirna in neutral liposomes |
CN102871956A (zh) * | 2012-10-29 | 2013-01-16 | 中南大学湘雅医院 | 一种治疗婴幼儿浅表血管瘤的盐酸普萘洛尔凝胶 |
CN107569485A (zh) * | 2017-07-24 | 2018-01-12 | 中南大学湘雅医院 | 一种治疗braf抑制剂耐药型黑色素瘤的复方制剂 |
CN110314154A (zh) * | 2018-03-28 | 2019-10-11 | 武汉恒信源药业有限公司 | 左旋普萘洛尔在制备治疗血管病变药物中的应用 |
Non-Patent Citations (5)
Title |
---|
MASAHIRO KOH ET AL.: "Propranolol suppresses gastric cancer cell growth by regulating proliferation and apoptosis", 《GASTRIC CANCER》 * |
MASAHIRO KOH ET AL.: "Propranolol suppresses gastric cancer cell growth by regulating proliferation and apoptosis", 《GASTRIC CANCER》, vol. 24, 29 March 2021 (2021-03-29), pages 1037, XP037527934, DOI: 10.1007/s10120-021-01184-7 * |
PING LIAO ET AL.: "Propranolol Suppresses the Growth of Colorectal Cancer Through Simultaneously Activating Autologous CD8+ T Cells and Inhibiting Tumor AKT/MAPK Pathway", 《CLINICAL PHARMACOLOGY & THERAPEUTICS》 * |
PING LIAO ET AL.: "Propranolol Suppresses the Growth of Colorectal Cancer Through Simultaneously Activating Autologous CD8+ T Cells and Inhibiting Tumor AKT/MAPK Pathway", 《CLINICAL PHARMACOLOGY & THERAPEUTICS》, vol. 108, no. 3, 30 September 2020 (2020-09-30), pages 606 - 615 * |
廖新华等: "普奈洛尔对胃癌放疗敏感性影响及其机制的实验研究", 《现代肿瘤医学》, vol. 26, no. 21, pages 3369 - 3373 * |
Also Published As
Publication number | Publication date |
---|---|
CN114224875B (zh) | 2023-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019165695A1 (zh) | 一种敲除GRIN2D基因的CRISPR-Cas9系统及其应用 | |
Xu et al. | EGF induces epithelial-mesenchymal transition and cancer stem-like cell properties in human oral cancer cells via promoting Warburg effect | |
Kreusel et al. | Cl-secretion in epithelial monolayers of mucus-forming human colon cells (HT-29/B6) | |
CN113444802B (zh) | Htr1a在乳腺癌诊断、治疗和预后中的应用 | |
CN114224875A (zh) | 醇类化合物的新用途及抗肿瘤药物 | |
CN116115759B (zh) | 联合抑制nat10/kif23的物质在制备防治结直肠癌药物中的应用 | |
CN111388651B (zh) | Cst-14在制备骨质疏松症治疗药物中的应用 | |
CN110013555B (zh) | Lrp11作为靶点在制备治疗宫颈癌的制品中的应用 | |
CN111856014A (zh) | 诊断和治疗膀胱癌的分子标志物mllt11及其用途 | |
CN114010792A (zh) | 联合用药物及其用途 | |
CN103976991A (zh) | Smc的应用及用于防治阿尔茨海默病的药物和保健品 | |
Williams et al. | Isolation and characterization of clonal cell lines from a transplantable metastasizing rat mammary tumor, TR2CL | |
CN108931633B (zh) | 胆囊癌诊断和预后判断标志物pim1 | |
CN108490180B (zh) | EphA8基因在制备胃癌药物及其诊断试剂盒中的应用 | |
CN107607727B (zh) | H3K23ac在胶质瘤诊断中的应用 | |
CN117805376B (zh) | CD44和Lgr5作为标记物在筛选胃癌肿瘤干细胞中的应用 | |
CN113209096B (zh) | 培西达替尼在制备预防、缓解和/或治疗心肌梗死及其相关疾病药物中的应用 | |
CN113116917B (zh) | 8-Br-cGMP作为PKG I激活剂在制备预防或治疗卵巢上皮癌药物中的应用 | |
CN105467119A (zh) | 一种预测大肠癌细胞对p38MAPK激酶抑制剂敏感性的方法 | |
CN117122669B (zh) | 重组人生长激素在治疗中枢尿崩症的应用 | |
CN118141931A (zh) | 增强sqstm1表达的物质在制备治疗急性肺损伤的药物中的应用 | |
CN114414805A (zh) | 与口腔鳞癌细胞生长相关的标志物及其应用 | |
CN116159154A (zh) | Kcp2基因及其慢病毒载体系统的应用 | |
CN113913519A (zh) | Cul9作为分子标志物在制备调控结直肠癌铁死亡中的应用 | |
CN116492348A (zh) | 靶向htr2b基因的化合物在制备治疗肿瘤的药物中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: He Yijing Inventor after: Zhang Yu Inventor after: Kuang Guichao Inventor after: Wang Shiyu Inventor after: Liao Xiaoxiao Inventor after: Long Jing Inventor after: Chen Xiang Inventor before: He Yijing Inventor before: Kuang Guichao Inventor before: Wang Shiyu Inventor before: Zhang Yu Inventor before: Liao Xiaoxiao Inventor before: Long Jing Inventor before: Chen Xiang |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |